- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01427257
Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus
Phase 1 Open-Label Two-Way Cross Over Study to Assess the Pharmacokinetic Profile of Two Formulations of PB1023 Injection Following a Single Dose Administered By Subcutaneous Injection in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)
Primary objective:
To compare the pharmacokinetic profile of PB1023 after a single dose administered by subcutaneous injection of two formulations (concentrations).
Secondary objectives:
To evaluate the safety and tolerability of two formulations of PB1023 Injection administered as a subcutaneous injection in adult subjects with T2DM.
To evaluate the impact on the pharmacokinetic profile of PB1023 after a single 90 mg dose of formulation B (100 mg/mL) administered cold at 2 to 8°C by subcutaneous injection.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Prism Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to sign a written informed consent and follow all study related procedures.
- Males or post menopausal or surgically sterile females age 18 - 75 years of age inclusive.
- Diagnosed with T2DM for ≥ 6 months.
- HbA1c of ≥ 6.0% if diet and exercise controlled, or ≥5.8% if taking one or more glucose lowering agents
- Weight ≥ 45 kg and BMI ≤ 40 kg/m2
- In otherwise stable health except for T2DM (no clinically significant laboratory abnormalities, vital signs, ECG findings or clinically significant underlying disease that would put the subject at risk for participation in the study).
- Receiving stable doses of concomitant medications for 30 days prior to dosing.
- Criteria for Participation in Period 3 only: Received PB1023 Injection at 50 mg/mL and 100 mg/mL during Period 1 or 2 of the study and had adequate pharmacokinetic samples collected for evaluation of their pharmacokinetic profile.
Exclusion Criteria:
- Currently taking Byetta® or Victoza®.
- Previously received PB1023 Injection other than under this study protocol.
- Known allergy or serious adverse effect to an approved or investigational GLP-1 receptor analog/agonist.
Unstable cardiovascular disease defined as:
- History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to the Screening visit.
- Screening (duplicate supine reading) BP ≥ 160 mmHg (systolic) or ≥ 100 mmHg (diastolic).
- Mean triplicate 12-lead ECG demonstrating QT interval (corrected) (QTc) > 450 msec in males and > 470 msec in females at the Screening visit, or a history or evidence of long QT syndrome.
Based on contraindications/warnings identified with other GLP-1 receptor agonists, subjects will be excluded if they have:
- History, symptoms or signs of pancreatitis or severe gastrointestinal disease (i.e., gastroparesis)
- Personal or family history of medullary thyroid tumors or history of Multiple Endocrine Neoplasia Syndrome Type 2. Note: Abnormal serum calcitonin at screening will exclude the subject from participation.
Clinically significant renal and/or hepatic dysfunction at screening as indicated by the following:
- eGFR as calculated by MDRD of < 60 mL/min
- Urine dipstick protein > 2+ (100 mg/dL) or urine protein 2+ and a Urine Protein/Creatinine ratio > 1.0 (> 1000 mg/g)
- Alanine aminotransferase (ALT) > 2 x ULN
- Aspartate aminotransferase (AST) > 2 x ULN
- Serum bilirubin ≥ 1.6 mg/dL
- Pregnant or lactating females
- Known history of or active alcohol or drug abuse within 12 months prior to Screening or positive alcohol and/or drug screen.
- Positive for Human Immunodeficiency Virus (HIV) antibodies, Hepatitis B surface antigen (HBsAg) or Hepatitis C Virus (HCV) antibodies.
- Participating in any other study and have received any other investigational drug or device within 30 days prior to the Screening visit or are taking part in a non-drug study which in the opinion of the Investigator would interfere with the outcome of the study.
- Other medical (i.e., acute or chronic illness) or psychiatric condition which in the opinion of the Investigator would place the subject at increased risk, confound the primary study endpoint, or would preclude obtaining voluntary consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: PB1023 Formulation A
|
Single Dose PB1023 Formulation A
Single Dose PB1023 Formulation B
|
ACTIVE_COMPARATOR: PB1023 Formulation B
|
Single Dose PB1023 Formulation A
Single Dose PB1023 Formulation B
|
ACTIVE_COMPARATOR: PB1023 Formulation B (2-8C)
|
Single Dose PB1023 Formulation A
Single Dose PB1023 Formulation B
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics
Time Frame: For each dosing period: Pre-dose, 1, 4, 8, 12 hours, 1, 2, 3, 4, 7 and 10 days post-dose
|
The pharmacokinetic profile of two formulations of PB1023 will be compared.
The following parameters will be evaluated: t1/2, AUC(inf), AUC(0-t), Tmax, Cmax, Elimination Rate Constant, Clearance and Distribution.
|
For each dosing period: Pre-dose, 1, 4, 8, 12 hours, 1, 2, 3, 4, 7 and 10 days post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety/Tolerability
Time Frame: 42 Days
|
Safety will be evaluated by analyses of incidence of adverse events of interest (possibly related to the class of drug) and other adverse events.
Vital signs, ECGs and safety laboratory parameters will also be presented.
|
42 Days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PB1023-PT-CL-0002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Single Dose PB1023
-
PhaseBio Pharmaceuticals Inc.Completed
-
PhaseBio Pharmaceuticals Inc.CompletedDiabetes Mellitus, Type 2United States
-
AblynxCompletedHealthy VolunteersUnited States
-
Taiho Pharmaceutical Co., Ltd.CompletedStress Urinary IncontinenceJapan
-
PfizerCompleted
-
Galapagos NVCompleted
-
Bridge Biotherapeutics, Inc.KCRN Research, LLCCompletedHealthy ParticipantsUnited States
-
Longbio PharmaRecruitingParoxysmal Nocturnal Hemoglobinuria (PNH)China
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China